CAN04

DRUG4 trials

Conditions

Advanced triple negative breast cancerCarcinoma, Non-Small-Cell LungColorectal CancerHead and Neck Squamous Cell CarcinomaMalignant MelanomaMetastatic Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Phase 1

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

CompletedNCT03267316

Cantargia ABColorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma +1

Start: 2017-09-19End: 2024-03-14Updated: 2024-08-22

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

CompletedNCT04452214

Cantargia ABCarcinoma, Non-Small-Cell Lung, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma +1

Start: 2020-09-24End: 2023-06-28Updated: 2023-07-14

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

CompletedNCT04990037

Cantargia ABMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2021-07-19End: 2023-06-15Updated: 2023-06-29

A randomized non-comparative open-label phase 1b/2 study of nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer “TRIFOUR study”

Active, not recruitingCTIS2024-512052-38-00

Cantargia ABAdvanced triple negative breast cancer

Start: 2021-12-02Target: 117Updated: 2025-09-01

Journal of Clinical Oncology2026-01-10

Abstract B091: Interleukin-1 Receptor Accessory Protein (IL1RAP) overexpression is associated with worse outcome in PDAC and can be reversed by nadunolimab treatment

Cancer Research2025-09-28

Abstract B006: Exploiting Myeloid-Stromal IL1RAP as a Therapeutic Vulnerability to Improve Chemoimmunotherapy Sensitivity in Pancreatic Cancer

Cancer Research2025-09-28

Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet.

2025-07-14

Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors

Investigational New Drugs2025-05-011 citations

Impact on chemotherapy induced peripheral neuropathy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in patients with pancreatic cancer, with supportive mouse model data.

Journal of Clinical Oncology2024-06-01

Abstract 2895: ILRAP blockade mediates anti-fibrotic effects in pancreatic cancer-associated fibroblasts

Cancer Research2024-03-22

Abstract C002: Interleukin-1 receptor accessory protein (IL1RAP) overexpression is associated with worse prognosis in PDAC and is targetable by nadunolimab

Cancer Research2024-01-161 citations

Safety, efficacy and biomarker data in patients with non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab in combination with platinum doublet.

Journal of Clinical Oncology2023-06-01

Abstract 6429: A surrogate to the anti-IL1RAP antibody nadunolimab induces tumor microenvironment changes to the metastatic lung and reduces metastatic lesions in mouse models of metastatic cancer

Cancer Research2023-04-04

Abstract C055: The IL1RAP-blocking antibody nadunolimab disrupts pancreatic cancer cell and fibroblast crosstalk, reduces recruitment of myeloid cells and inhibits tumor growth

Cancer Research2022-11-15

145 Nadunolimab inhibits IL-1α/β-induced CXCR1/2 ligand expression and reduces serum levels of CXCL1 and CXCL5 in NSCLC and PDAC patients

Regular and Young Investigator Award Abstracts2022-11-01

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2022-06-017 citations

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology2022-06-016 citations

Safety, tolerability, and preliminary efficacy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in combination with pembrolizumab in subjects with solid tumors.

Journal of Clinical Oncology2022-06-013 citations

Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor

Frontiers in Immunology2021-12-2423 citations

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

British Journal of Cancer2021-12-1324 citations

Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.

Journal of Clinical Oncology2021-05-202 citations

Abstract 2269: The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy

Cancer Research2020-08-154 citations

Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies.

Journal of Clinical Oncology2019-05-205 citations

1 more papers not shown

CAN04

Sponsors

Conditions

Phase 1

Related Papers